目的研究支气管哮喘患儿呼出气一氧化氮(Fe NO)数值在诊断及疗效判断中的价值。方法选取确诊的哮喘患儿60例随机分成吸入糖皮质激素(ICS)组与免疫治疗组各30例,选取同期就诊的25例非呼吸道疾病儿童为正常对照组。免疫治疗组采用口服匹多莫德进行治疗,ICS组采用吸入布地奈得气雾剂进行治疗。检测治疗前及治疗3个月后两组患儿的FeNO值与正常对照组比较,同时记录两组患儿治疗后疗效情况。结果治疗前ICS组和免疫治疗组Fe NO值差异无统计学意义(P>0.05),但均高于正常对照组(P<0.01);治疗3个月后两组患儿症状均有所改善,Fe NO值较治疗前均有所降低且ICS组降低更明显,差异有统计学意义(P<0.05),但两组Fe NO值仍高于正常对照组差异有统计学意义(P<0.05)。结论 Fe NO升高是儿童支气管哮喘气道炎症的标志,通过监测Fe NO的变化可用于评估炎症情况并指导哮喘的规范治疗。 Objective To investigate the value of exhaled nitric oxide (NO) in the diagnosis and therapeutic effect of bronchial asthma in children. Methods Sixty children diagnosed with asthma were randomly divided into 30 patients in ICS group and immunotherapy group, and 25 non-respiratory disease children in the same period were selected as normal control group. The immunotherapy group was treated with oral pidotimod and the ICS group was treated with inhaled budesonide aerosol. Before treatment and 3 months after treatment, the FeNO values ​​in both groups were compared with those in the normal control group, and the therapeutic effects of both groups were also recorded. Results There was no significant difference in FeNO between ICS group and immunotherapy group before treatment (P> 0.05), but both of them were higher than those of normal control group (P <0.01). After 3 months of treatment, the symptoms of both groups were improved (P <0.05). However, there was a significant difference between the two groups (P> 0.05), but the FeNo value was lower than that of the normal control group (P <0.05) ). Conclusion Elevated Fe NO is a marker of airway inflammation in children with bronchial asthma. It can be used to evaluate the inflammation and guide the standardized treatment of asthma by monitoring the changes of Fe NO.